Given the relationship between the degree of MAPK inhibition and induction of immune program gene expression in tumor cells, these findings also raise the possibility that improved MAPK inhibition through a more optimal BRAF-targeted combination could drive greater immune cooperativity and greater clinical efficacy in combination with ICB. Here, BRAF is linked to neoplasm.